Insilico Medicine Secures $110M Series E Funding, Achieves Unicorn Status for AI-Driven Drug Discovery
核心洞察
Insilico Medicine (搜索) has raised $110 million in Series E financing led by Value Partners Group (搜索), valuing the company at over $1 billion and officially achieving unicorn status.
The AI drug discovery company will use funds to advance its lead candidate Rentosertib (搜索) for idiopathic pulmonary fibrosis (搜索), which has shown promising results in Phase IIa trials, and expand its portfolio of 30 AI-discovered drug candidates.
Insilico's proprietary Pharma.AI (搜索) platform has demonstrated ability to reduce drug discovery timelines to 12-18 months compared to traditional 2.5-4 years, while requiring significantly fewer test molecules.
Insilico Medicine (搜索), a clinical-stage biotechnology company specializing in AI-driven drug discovery, has successfully secured $110 million in Series E financing, propelling the company to unicorn status with a valuation exceeding $1 billion. The funding round was led by a private equity fund of Value Partners Group (搜索), one of Asia's largest independent asset management firms, with participation from both new industry and technology-focused investors as well as existing global backers.
The Hong Kong and Boston-based company will direct the newly raised capital toward advancing its innovative drug pipeline and enhancing its AI platform capabilities. The financing comes at a critical time as Insilico's lead drug candidate for idiopathic pulmonary fibrosis (搜索) shows promising clinical results.
AI Platform Accelerating Drug Discovery
Insilico's proprietary Pharma.AI (搜索) platform has demonstrated remarkable efficiency in drug discovery, reducing the average time to preclinical candidate nomination to just 12-18 months, compared to the 2.5-4 years typically required by traditional methods. The platform achieves this while testing only 60-200 molecules per program, significantly fewer than conventional approaches.
Dr. Chuen Yan Leung, Partner (Healthcare Investments) at Value Partners, expressed enthusiasm about the partnership: "We are excited to partner with Insilico Medicine (搜索) in its mission to transform drug discovery with AI and automation. With a proven track record and a leadership position in AI-driven drug development, Insilico is at the forefront of transforming the industry."
The Pharma.AI (搜索) platform undergoes major updates twice yearly to maintain its technological edge. Built around generative AI, it provides comprehensive solutions spanning biology, chemistry, clinical medicine, and scientific research. Recent enhancements include Nach01, a multimodal foundation model for natural and chemical languages, and Dora, a multi-agent generative research assistant.
In a notable advancement, Insilico has deployed the first bipedal humanoid AI Scientist within Life Star1, its fully robotic laboratory in Suzhou, China. This integration of robotics and AI aims to further optimize and automate research workflows.
Promising Clinical Progress with Rentosertib
The company's most advanced candidate, Rentosertib (搜索) (formerly known as ISM001-055), has shown encouraging results in treating idiopathic pulmonary fibrosis (搜索) (IPF), a progressive and incurable lung disease with significant unmet medical needs.
In a completed Phase IIa clinical trial, Rentosertib (搜索) demonstrated favorable safety and tolerability across all dose levels, along with dose-dependent response in forced vital capacity (FVC) after only 12 weeks of treatment. These positive results position Rentosertib as a potential breakthrough in IPF treatment.
"If, in the next five years, we can get Rentosertib (搜索) approved, we will make history," said Alex Zhavoronkov, Founder and CEO of Insilico Medicine (搜索), highlighting the significance of this development.
Sustainable Business Model Through Strategic Partnerships
Insilico has established a sustainable revenue stream through strategic out-licensing deals and collaborations. The company has secured four pipeline out-licensing agreements with Fosun Pharma, Exelixis, and Menarini, collectively valued at over $2.1 billion.
Additionally, Insilico has initiated multiple drug discovery and development collaborations with industry partners including Sanofi, Saudi Aramco, and Therasid Bioscience, with a combined value exceeding $1.4 billion. Many of these partnerships have reached milestones, resulting in payments to Insilico and contributing to the company's growing financial performance.
Future IPO Considerations
Despite filing for Hong Kong initial public offerings in 2023 and 2024, both applications lapsed in what was described as a lukewarm market. Zhavoronkov indicated that the company is still considering going public in Hong Kong but declined to provide a specific timeline.
"We didn't go IPO last year because we were waiting for the Phase 2 readout [of Rentosertib (搜索)]," Zhavoronkov explained. "If it would be up to me, I would do it quicker because right now it's a very favorable market environment."
The AI drug discovery landscape has seen increased investor interest, with Insilico's peer Xtalpi (搜索) going public in Hong Kong in a $127 million IPO in June 2024. Shares of the Shenzhen-based company have risen more than 20% since then, reflecting growing enthusiasm for AI applications in pharmaceutical research.
Expanding the Drug Discovery Portfolio
To date, Insilico has rapidly built a wholly-owned drug discovery portfolio of 30 assets driven by its Pharma.AI (搜索) platform, with 10 of these assets receiving Investigational New Drug (IND) clearance. This impressive pipeline demonstrates the scalability and effectiveness of the company's AI-driven approach.
With the successful completion of its Series E financing, Insilico is positioned to further accelerate the advancement of AI-powered biopharmaceutical research and development, strengthen collaboration across the industry value chain, and drive the application of its cutting-edge AI platform in diverse scenarios within the life sciences sector.